207940.KS实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 14:30):

Stats
今日成交量	56 064.00
平均成交量	64 103.00
市值	54 875.15B
EPS	KRW0 ( 2024-04-24 )
下一个收益日期	( KRW2 823.26 ) 2024-07-24
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW1 059.41 (0.14%)

音量相关性

長: -0.14 (neutral)

短: -0.54 (weak negative)

Signal:(44.009) Neutral

Samsung Biologics 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Samsung Biologics 相关性 - 货币/商品

-0.30
( neutral )

0.00
( neutral )

-0.19
( neutral )

0.21
( neutral )

0.28
( neutral )

0.22
( neutral )

Samsung Biologics 财务报表

Annual	2023
营收:	KRW3 694.59B
毛利润:	KRW1 802.76B (48.79 %)
EPS:	KRW12 050

FY	2023
营收:	KRW3 694.59B
毛利润:	KRW1 802.76B (48.79 %)
EPS:	KRW12 050

FY	2022
营收:	KRW3 001.30B
毛利润:	KRW1 468.45B (48.93 %)
EPS:	KRW11 442

FY	2021
营收:	KRW1 568.01B
毛利润:	KRW726.45B (46.33 %)
EPS:	KRW5 948.61

Financial Reports:

No articles found.

Samsung Biologics

Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.